SCHEMBL25207237

SCHEMBL25207237

Cc1cc(C(C)(C)O)cc(C)c1C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.47
ACHE P22303 1/20 0.47
KDM4E B2RXH2 3/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
MAPK1 P28482 3/20 0.44
ALDH1A1 P00352 3/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
GLRA3 O75311 1/20 0.42
GLRB P48167 1/20 0.42
MAPT P10636 3/20 0.40
NOTUM Q6P988 1/20 0.39
KMT2A Q03164 4/20 0.39
POLB P06746 2/20 0.39
MEN1 O00255 3/20 0.38
LDHA P00338 2/20 0.38
LDHB P07195 2/20 0.38
RXRB P28702 2/20 0.37
HPGD P15428 1/20 0.36
ALOX15 P16050 1/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5581647 0.84 CYP3A4 (0.48) CYP3A4ACHEKDM4EL3MBTL1MAPK1
SCHEMBL501930 0.84 RXRB (0.50) CYP3A4ACHEKDM4EL3MBTL1MAPK1
SCHEMBL4642911 0.81 CYP3A4 (0.50) CYP3A4ACHEKDM4EL3MBTL1MAPK1
SCHEMBL9934240 0.80 GLRA3 (0.45) CYP3A4ACHEKDM4EL3MBTL1MAPK1
SCHEMBL30435110 0.80 POLB (0.46) KDM4EL3MBTL1MAPTKMT2APOLB
SCHEMBL422352 0.77 RXRA (0.51) CYP3A4ACHEKDM4EL3MBTL1MAPK1
SCHEMBL9973268 0.77 KDM4E (0.45) CYP3A4ACHEKDM4EL3MBTL1MAPK1
SCHEMBL15957693 0.77 CYP3A4 (0.42) CYP3A4ACHEKDM4EL3MBTL1MAPK1
SCHEMBL21870 0.75 KDM4E (0.55) CYP3A4ACHEKDM4EL3MBTL1MAPK1
SCHEMBL377596 0.75 KDM4E (0.55) CYP3A4ACHEKDM4EL3MBTL1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230322785-A1 ADENOSINE A2A AND A2B RECEPTOR DUAL ANTAGONISTS FOR IMMUNO-ONCOLOGY MERCK SHARP & DOHME LLC (US) 2023-10-12 US disclosed
US-20230322785-A1 ADENOSINE A2A AND A2B RECEPTOR DUAL ANTAGONISTS FOR IMMUNO-ONCOLOGY MERCK SHARP & DOHME LLC (US) 2023-10-12 US disclosed
US-20230322785-A1 ADENOSINE A2A AND A2B RECEPTOR DUAL ANTAGONISTS FOR IMMUNO-ONCOLOGY MERCK SHARP & DOHME LLC (US) 2023-10-12 US disclosed
EP-4185296-A1 ADENOSINE A2A AND A2B RECEPTOR DUAL ANTAGONISTS FOR IMMUNO-ONCOLOGY Merck Sharp & Dohme LLC (US) 2023-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322785-A1 ADENOSINE A2A AND A2B RECEPTOR DUAL ANTAGONISTS FOR IMMUNO-ONCOLOGY ADORA2A, ADORA2B, ADORA1 CYP3A4 3316/4885ACHE 4746/4885KDM4E 3663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.